Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

Bacterial Keratitis Clinical Trial

Official title:

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking With Corneal Thinning Conditions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04213885
• Other study ID #: PXL330-001
• Status: Recruiting
• Phase: Phase 2
• Start date: May 4, 2020
• Est. completion date: September 1, 2030

Study information

• Verified date: February 2023
• Source: Eye Specialists of Indiana
• Contact: Clark L Springs, MD
• Phone: 317-925-2200
• Email: csprings[@]iupui.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.

Description:

Patients with progressive keratoconus, pellucid marginal degeneration, infectious keratitis, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, intraocular pressure and visual function questionnaire.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: September 1, 2030
• Est. primary completion date: September 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:Criterion 1,2,3 are required for all participants. Participants must also meet one or more of criteria 4-12. Criteria 13 is only relevant for contact lens wearers.

1. 12 years of age or older

2. Signed written informed consent

3. Willingness and ability to comply with schedule for follow-up visits

4. Presence of central or inferior steepening

5. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration

6. Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as

1. Fleisher ring

2. Vogt's striae

3. Decentered corneal apex

4. Munson's sign

5. Rizzutti's sign

6. Apical corneal scarring consistent with Bowman's breaks

7. Scissoring of the retinoscopic reflex

8. Crab-claw appearance on topography

7. Steepest keratometry (Kmax) value greater than or equal to 47.2

8. I-S keratometry difference < 1.5 D on the Pentacam map or topography map

9. Posterior corneal elevation > 16 microns

10. Thinnest corneal point <485 microns

11. Predicted Post LASIK/PRK stromal ablation depth <350 microns or expected keratometry >47.2, or patients undergoing PRK/SMILE in keratoconus suspect eyes

12. Bacterial or fungal keratitis persistent and not responding despite > 2 weeks of standard antimicrobial therapy or with rapid progression of corneal thinning, with loss of >25% corneal thickness

13. Contact lens wearers only:

1. Removal of contact lenses for the require period of time prior to the screening refraction:

Contact Lens Type Discontinuations Time: Soft, 1 week; Soft Extended Wear, 2 weeks; Soft Toric, 3 weeks; Rigid Gas Permeable, 2 weeks per decade of wear -

Exclusion Criteria:

1. Eyes classified as normal or atypical normal on the severity grading scheme

2. Corneal pachymetry at the screening exam that is <300 microns at the the thinnest point in the eye(s) to be treated.

3. Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:

1. History of or active corneal disease (e.g. herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthamoeba, etc.)

2. Clinically significant corneal scarring the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.

4. Pregnancy (including plan to become pregnant) or lactation during the course of the study

5. A known sensitivity to the study medications

6. Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment of diagnostic tests.

7. Patients with a current condition that, in the physician's opinion, wold interfere with or prolong epithelial healing.

-

Related Conditions & MeSH terms

• Bacterial Keratitis
• Ectasia Corneal
• Keratitis
• Keratoconus
• Keratoconus, Unstable

Intervention

Combination Product:
• PXL 330 Platinum device/Riboflavin
30mW, 5 sec, 5 sec off, 10 minutes of illumination

Locations

Country	Name	City	State
United States	Eye Specialists of Indiana	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Eye Specialists of Indiana

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean keratometry in diopters	Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer	1 year
Secondary	Best corrected visual acuity	Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale	1 year